Table 5.

Relationship between IBD-SES subscales and patient-reported outcomes

Symptom domain	Original Keefer et al model			4-factor EFA model			3-factor EFA model
	β	95% CI	P	β	95% CI	P	β	95% CI	P
Daily life impact
Self-efficacy for managing stress and emotion	−0.12	−0.20 to −0.05	0.001	−0.11	−0.16 to −0.05	<0.001	−0.11	−0.16 to −0.05	<0.001
Self-efficacy for managing symptoms and disease	−0.28	−0.35 to −0.20	<0.001	−0.25	−0.31 to −0.19	<0.001	−0.24	−0.30 to −0.18	<0.001
Systemic symptoms
Self-efficacy for managing stress and emotion	−0.06	−0.090 to −0.03	<0.001	−0.05	−0.08 to −0.03	<0.001	−0.05	−0.08 to −0.03	<0.001
Self-efficacy for managing symptoms and disease	−0.12	−0.15 to −0.09	<0.001	−0.10	−0.12 to −0.07	<0.001	−0.09	−0.12 to −0.07	<0.001
Required coping strategies
Self-efficacy for managing stress and emotion	−0.02	−0.04 to −0.002	0.030	−0.02	−0.04 to −0.01	0.007	−0.02	−0.04 to −0.01	0.007
Self-efficacy for managing symptoms and disease	−0.07	−0.09 to −0.05	<0.001	−0.06	−0.08 to −0.05	<0.001	−0.06	−0.08 to −0.04	<0.001
Emotional impact
Self-efficacy managing stress and emotion	−0.21	−0.26 to −0.16	<0.001	−0.17	−0.21 to −0.13	<0.001	−0.17	−0.21 to −0.13	<0.001
Self-efficacy for managing symptoms and disease	−0.23	−0.29 to −0.16	<0.001	−0.19	−0.24 to −0.14	<0.001	−0.18	−0.23 to −0.13	<0.001

CI, confidence interval; EFA, exploratory factor analysis; IBD, inflammatory bowel disease; IBD-SES, IBD Self-Efficacy Scale.

Adjusted for age, sex, IBD, type, disease activity, moderate-to-severe disease, depression, and anxiety.